Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna photopheresis coverage & prior auth | OpenPa…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0241

    Extracorporeal Photochemotherapy (Photopheresis)

    Customize your policy alerts

    Sign up for Aetna Policy 0241 alerts

    Get alerted when Policy 0241 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Aetna clinical policy bulletin defines when extracorporeal photochemotherapy (ECP, photopheresis) is considered medically necessary, lists indications considered experimental/investigational, and provides related coding and background information for providers and payers.

    Policy Summary
    PayerAetna
    PolicyExtracorporeal Photochemotherapy (Photopheresis)
    Policy CodePolicy 0241
    Change TypeNo material change
    Effective DateMay 7, 1998
    Last ReviewMar 29, 2023
    Next Review DateFeb 22, 2024
    Key ActionObtain prior authorization for CPT 36522 when requesting photopheresis for listed medically necessary diagnoses.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5+Medically necessary indications listed
    21+Experimental/Investigational indications
    36522Primary CPT code
    1988FDA approval
    03/29/2023Last review

    Coverage Criteria for Extracorporeal Photochemotherapy (ECP)

    inv-01: Medically Necessary Indications

    Aetna considers ECP medically necessary when the following indication-specific conditions are met:

    Medically necessary indications list: 1. Erythrodermic variants of cutaneous T‑cell lymphoma (e.g., mycosis fungoides, Sézary syndrome).

    FDA‑approved indication; see policy statement.

    Acute cardiac allograft rejection (medically necessary when):

    • Refractory requirement: Resistant or dependent to high‑dose corticosteroids AND refractory to ≥2 of the listed immunosuppressive agents unless contraindicated.≥2 agents

      As specified in the policy.

    Lung transplant rejection (bronchiolitis obliterans) (medically necessary when):

    • Rapid decline exception: Rapid decline in lung function may justify ECP even if other refractory criteria are not fully met.

      Policy allows use with rapid FEV1 decline.

    Other solid organ transplant rejection (last‑resort): As a last‑resort treatment for rejection of other solid organ transplants when the disease is refractory to standard immunosuppressive drug treatment.

    Intended for refractory cases after standard therapies have failed.

    Graft‑versus‑host disease (GVHD): Treatment of graft‑versus‑host disease of an allogeneic bone marrow or stem cell transplant when the disease is refractory to standard immunosuppressive drug treatment.

    Refractory GVHD (steroid‑refractory or failed standard therapies) per policy.

    inv-02: Experimental/Investigational (Not Medically Necessary)

    ECP is considered experimental and investigational for the following indications because effectiveness has not been established:

    Experimental/Investigational indications list: Atopic dermatitis; autoimmune diseases; bronchiolitis obliterans syndrome after allogeneic stem cell transplantation; bullous pemphigoid; colitis associated with checkpoint‑inhibitor therapy; Crohn’s disease; eosinophilic fasciitis; epidermolysis bullosa acquisita; graft rejection in kidney transplant recipients; morphea (localized scleroderma); multiple sclerosis; nephrogenic systemic fibrosis; pemphigus vulgaris; pityriasis rubra pilaris; prophylaxis of graft‑versus‑host disease after allogeneic hematopoietic cell transplantation; prophylactic use to reduce infective complications after kidney transplantation; scleroedema adultorum Buschke; stage 0‑p bronchiolitis obliterans syndrome; systemic sclerosis (scleroderma); type 1 diabetes; xanthogranulomas.

    Policy notes list is not all‑inclusive.

    inv-03: Study-based inclusion descriptors

    Clinical contexts where ECP has been studied (evidence‑based inclusion descriptors):

    Atopic dermatitis (study inclusion): Disease duration ≥1 year; SCORAD >45; resistance to first‑line therapy (topical steroids, topical calcineurin inhibitors, and one form of phototherapy) or failure of one second‑line therapy (systemic steroids or cyclosporine).SCORAD >45

    Derived from a 20‑week prospective study; treatment schedule described as 2 sessions in 2‑week intervals for 12 weeks then 4‑week intervals to week 20.

    Prophylactic ECP after kidney transplant (study protocol): ECP administered as 10–15 sessions during the first 6 months (reported as 10–15 or 12–16 applications in study reports) in addition to conventional immunosuppression immediately after transplant; outcomes monitored by graft function and infection rates.10–16 applications

    Small randomized/paired cohort studies reported lower infection rates and improved intermediate outcomes; findings preliminary and require further validation.

    Stage 0‑p BOS descriptor:

    inv-04: Evidence summaries by clinical indication

    Indications and clinical contexts described in this portion of the policy (evidence summary):

    BOS/CLAD after transplant (evidence summary): Small retrospective studies and audits report that ECP may arrest decline in lung function and improve survival in some cohorts; one 12‑patient rescue series reported a 67% response rate (arrested FEV1 decline). Evidence is limited and requires prospective validation.~67% response in small series

    Findings from retrospective/small studies; prospective trials needed.

    Prophylactic ECP after kidney transplantation (evidence summary): A small paired randomized/open cohort reported reduced infective complications and higher 6‑year survival (100% vs 82.8%) with prophylactic photopheresis plus standard immunosuppression compared with immunosuppression alone; results are preliminary.6‑year survival 100% vs 82.8%

    Small study; requires confirmation.

    Scleroedema adultorum and related skin disorders (evidence summary):

    The policy lists several ICD-10 diagnoses for which use of extracorporeal photochemotherapy (ECP) is considered not covered for the indications described in this Clinical Policy Bulletin. Examples include autoimmune and dermatologic conditions such as L20.0-L20.9 (Atopic dermatitis), L10.0-L10.9 (Pemphigus), L12.0-L12.9 (Pemphigoid), L94.0 (Localized scleroderma [morphea]), and other systemic autoimmune diagnoses (for example, G35 (Multiple sclerosis), K50.00-K50.919 (Crohn’s disease)).

    The Centers for Medicare & Medicaid Services (CMS) National Coverage Determination specifies that ECP for treatment of bronchiolitis obliterans syndrome (BOS) following lung allograft transplantation is covered only when provided under an approved clinical research study that meets specified criteria; CMS concluded evidence is insufficient for general coverage outside qualifying clinical research.

    A 2022 systematic review and meta-analysis of randomized trials in systemic sclerosis identified 3 RCTs (162 randomized, 132 analyzed) and found pooled results showed no significant benefit of ECP on skin scores (standardized mean difference = -0.11; 95% CI -0.45 to 0.23), leading to the conclusion that current randomized evidence is insufficient to support ECP as an effective therapy for systemic sclerosis.

    This Clinical Policy Bulletin provides a general description of plan or program benefits to assist in administration of coverage determinations. It does not constitute a contract and does not guarantee coverage; providers remain responsible for medical advice and for confirming member benefits under the applicable plan.

    A CMS decision memorandum (2006) concluded that available evidence was insufficient to support the use of ECP for autoimmune blistering disorders such as pemphigus vulgaris and bullous pemphigoid; accordingly, ECP for these indications is considered not supported by the evidence in this policy.

    Evidence for ECP in morphea and several other dermatologic conditions is limited to single-case reports, small case series, or combinational treatment reports. An UpToDate review cited in the policy notes little evidence to support efficacy for morphea and related skin disorders, and the policy therefore considers these indications unestablished.

    For systemic sclerosis and other indications supported only by case reports or small series, the policy characterizes the evidence as limited and insufficient. For example, scleroedema adultorum Buschke reports are primarily case reports and small series, and randomized controlled trials are lacking; similarly, pooled RCT data in systemic sclerosis did not show benefit. As a result, ECP for these indications is considered investigational or unsupported by high-quality evidence.

    Coding and Billing for Photopheresis

    Covered CPT Codes (if selection criteria are met)CPTCovered
    36522Photopheresis; extracorporeal
    Related CPT CodesCPT
    38204-38230Bone marrow or stem cell services and procedures
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
    ICD-10 Codes covered if selection criteria are metICD-10Covered
    C84.00-C84.09Mycosis fungoides
    C84.10-C84.19Sezary's disease
    C84.A0-C84.A9Cutaneous T-cell lymphoma, unspecified
    D89.810-D89.813Graft-versus-host disease
    J42Unspecified chronic bronchitis [only covered for rejection (bronchiolitis obliterans) in lung transplants]
    T86.00-T86.09Complications of bone marrow transplant
    T86.20-T86.39Complications of heart and heart-lung transplant
    T86.810-T86.819Complications of lung transplant
    Z94.1Heart transplant status
    Z94.81Bone marrow transplant status
    ICD-10 Codes listed as not covered for indications in this CPB (not all-inclusive)ICD-10Not Covered
    D51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiency [pernicious (congenital) anemia]
    D59.0-D59.1Acquired autoimmune hemolytic anemia
    D69.0Allergic purpura
    D76.3Other histiocytosis syndromes [Xanthogranulomas]
    L20.0-L20.9Atopic dermatitis
    G35Multiple sclerosis
    K50.00-K50.919Crohn's disease [regional enteritis]

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Obtain prior authorization for CPT 36522

    Prior authorization is required for CPT 36522 (photopheresis; extracorporeal) when used for indications — coverage is limited to the medically necessary diagnoses listed in the policy (e.g., erythrodermic cutaneous T‑cell lymphoma, refractory transplant rejection, refractory GVHD).

    • CPT code: 36522
    Prior Authorization

    CMS limits BOS coverage to qualifying clinical research

    ECP to treat bronchiolitis obliterans syndrome (BOS) after lung allograft transplantation is covered by CMS only when provided under an approved clinical research study; absence of qualifying clinical research documentation may result in denial or noncoverage.

    • CMS NCD (April 30, 2012): coverage limited to qualifying clinical research studies for BOS after lung transplant

    Background and Evidence Context

    Extracorporeal photochemotherapy, commonly called photopheresis or ECP, is an immunomodulatory leukapheresis procedure in which the patient ingests the photosensitizing agent 8‑methoxypsoralen (8‑MOP), whole blood is withdrawn, leukapheresis is performed, and the collected leukocytes are exposed extracorporeally to ultraviolet‑A (UVA) light before being reinfused. The procedure was FDA‑approved in 1988 for cutaneous T‑cell lymphoma and is believed to act via immunomodulatory effects on treated lymphocyte populations.

    Photopheresis is typically performed on 2 consecutive days at 4‑week intervals with clinical evaluation at about 6 months to assess response; those with improvement are maintained on the schedule until maximal clearing and usually receive an additional 6 months of treatment before gradual weaning.

    Definitions and Key Terms

    Extracorporeal photochemotherapy (photopheresis, ECP) — definition and short description
    DefinitionAn immunomodulatory leukapheresis technique in which patients ingest the photosensitizer 8-methoxypsoralen (8-MOP), leukocytes are collected by leukapheresis, exposed extracorporeally to ultraviolet-A (UVA) light, and the photo‑irradiated cells are reinfused into the patient.
    Procedure timingTypically performed on 2 consecutive days at 4-week intervals with clinical evaluation at 6 months to assess response; responders are maintained on the schedule until maximum clearing and then gradually weaned.
    Regulatory statusFDA approved in 1988 for treatment of cutaneous T‑cell lymphoma (erythrodermic variants).
    Stage 0-p BOS — definition (FEV1 decline criteria)
    DefinitionStage 0‑p bronchiolitis obliterans syndrome (BOS) is defined as an average decline in FEV1 of 10–19% from baseline measured on 2 occasions at least 3 weeks apart.

    Policy Revision History

    1998-05-07effective_date

    Policy became effective on 1998-05-07.

    2023-03-29last_review

    Policy was last reviewed on 2023-03-29.

    2024-02-22next_reviewLatest

    Next scheduled review date listed as 2024-02-22.

    Policy Summary
    PayerAetna
    PolicyExtracorporeal Photochemotherapy (Photopheresis)
    Policy CodePolicy 0241
    Change TypeNo material change
    Effective DateMay 7, 1998
    Last ReviewMar 29, 2023
    Next Review DateFeb 22, 2024
    Key ActionObtain prior authorization for CPT 36522 when requesting photopheresis for listed medically necessary diagnoses.
    SourceLink
    On This Page
    Coverage Criteria for Extracorporeal Photochemotherapy (ECP)Coding and Billing for PhotopheresisProvider Actions, Prior Authorization, and DocumentationBackground and Evidence ContextDefinitions and Key TermsPolicy Revision History
    Stage 0‑p defined as average decline in FEV1 of 10–19% on two measurements ≥3 weeks apart; considered predictive of BOS but not diagnostic.
    FEV1 decline 10–19%

    Descriptive inclusion criterion used in BOS/CLAD studies.

    Evidence consists primarily of case reports and small series suggesting potential benefit; high‑quality trials are lacking.
    case reports/series only

    Requires randomized trials for confirmation.

    Checkpoint‑inhibitor associated colitis (evidence summary): A single case report described complete resolution of refractory checkpoint‑inhibitor colitis after repeated ECP cycles; data are limited to case reports.single case report

    Insufficient evidence to generalize.

    Eosinophilic fasciitis (evidence summary): Very limited evidence (small case series, e.g., ≤6 cases) with some reports of benefit in steroid‑resistant disease; not established as standard therapy.case series (n≤6)

    UpToDate does not list ECP as standard option.

    Kidney transplant rejection (evidence summary): Retrospective multicenter series (n=33) suggest ECP may stabilize kidney function in a subset (33% stabilized at 12 months) with 61% graft survival at 12 months; benefit appears greater when initiated early and in certain rejection subtypes.stabilization in 33% at 12 months; graft survival 61%

    Evidence from retrospective cohorts; role needs further definition.

    Atopic dermatitis (evidence summary): Retrospective single‑center series (n=60) reported normalization of several biomarkers and clinical response in almost two‑thirds of patients after ECP, but interpretation limited by retrospective design and concomitant therapies.~66% clinical response in series

    Further controlled studies needed.

    Systemic sclerosis (evidence summary): Meta‑analysis of 3 randomized controlled trials (162 randomized, 132 analyzed) found no significant pooled benefit of ECP on skin scores (SMD −0.11; 95% CI −0.45 to 0.23); evidence does not support superiority.SMD −0.11 (95% CI −0.45 to 0.23)

    Pooled RCT data insufficient to support ECP for systemic sclerosis.

    Prior Authorization

    Recommend prior authorization for investigational or limited‑evidence uses

    Obtain prior authorization or pre-authorization documentation for indications supported primarily by small or inconclusive studies (for example, systemic sclerosis and other investigational uses); prior authorization is recommended to allow review of the evidence and justification.

    • Policy recommends prior authorization for limited or investigational indications supported by small studies or meta-analyses
    Prior Authorization

    Confirm plan benefits and prior‑auth rules with the member’s plan

    Verify the member’s plan provisions and prior authorization requirements with the payer; the Clinical Policy Bulletin provides review and effective dates but does not replace plan-specific benefit verification.

    • Policy history: Effective 05/07/1998; Last review 03/29/2023; Next review 02/22/2024
    • Clinical Policy Bulletins do not constitute a contract — confirm plan benefits
    Step Therapy

    Document refractory‑to‑standard‑therapy status for transplant rejection

    For transplant rejection indications, document that disease is refractory to standard immunosuppressive drug treatment (resistant or dependent to high‑dose steroids plus failure of ≥2 listed agents) before requesting ECP.

    • Refractory requirement: resistant/dependent to high‑dose steroids plus refractory to ≥2 of azathioprine, cyclosporine, methotrexate, or polyclonal/monoclonal antilymphocyte agents (e.g., ALG, ATG)
    Documentation Required

    Show failure of first‑line therapies in clinical documentation

    Clinical reports and trials generally describe ECP as a later‑line therapy used after failure of first‑line treatments (e.g., systemic corticosteroids, topical agents, phototherapy) — include prior therapy history in the request.

    • Studies report prior failure of first‑line therapies (topical steroids, calcineurin inhibitors, phototherapy) and sometimes second‑line agents
    Note

    Use ECP after standard therapies have failed or are contraindicated

    Consider ECP only after standard therapies have failed or are contraindicated for transplant rejection and immune‑related adverse events; requests for earlier use should include strong justification and supporting evidence.

    • Policy states ECP generally considered after standard therapies have failed or are contraindicated; case reports exist for checkpoint‑inhibitor colitis
    Step Therapy

    No formal step‑therapy program stated in this policy

    There are no formal step therapy requirements specified in this policy; however, clinical criteria require prior failure of standard therapies for many covered indications.

    • Policy: “No step therapy requirements are specified in this portion of the document.”
    • Medically necessary indications specify refractory-to-treatment thresholds
    Documentation Required

    Document procedure steps and usual treatment schedule

    Photopheresis involves oral 8‑methoxypsoralen ingestion, leukapheresis with UVA exposure of collected leukocytes, and reinfusion; typical schedule is two consecutive days every 4 weeks with clinical evaluation at 6 months.

    • Procedure: oral 8‑MOP followed ~2 hours later by leukapheresis, UVA exposure, reinfusion
    • Treatment schedule: usually 2 consecutive days at 4‑week intervals with evaluation at 6 months
    Documentation Required

    Include specific study‑based inclusion criteria in justification

    When studies are cited, include the trial inclusion details in the authorization request (for example: disease duration ≥1 year, SCORAD >45, and prior failure of first‑line and second‑line therapies in atopic dermatitis trials).

    • Atopic dermatitis trial inclusion: disease duration ≥1 year; SCORAD >45; resistance to first‑line therapy or one second‑line therapy
    Documentation Required

    Provide comprehensive clinical documentation and objective measures

    Include detailed clinical documentation: diagnosis, prior therapies and responses (e.g., steroid‑refractory GVHD or refractory colitis), objective measures when available (FEV1 decline for CLAD/BOS; baseline and follow‑up skin scores), and rationale for ECP given limited evidence.

    • Required documentation examples: diagnosis, prior treatments and outcomes, objective measures (FEV1, SCORAD, skin scores), rationale for ECP use
    Note

    Verify benefits — CPB is not a coverage guarantee

    Refer to the Clinical Policy Bulletin and the member’s plan provisions for benefit details; the bulletin provides only a partial description of plan benefits and is not a substitute for plan verification.

    • Clinical Policy Bulletins are developed to assist plan administration and do not constitute a contract
    Denial Risk

    Avoid or justify non‑covered ICD‑10 diagnoses to prevent denial

    If the submitted diagnosis is among the ICD‑10 codes listed as not covered for indications in this CPB (for example, L20.0–L20.9, G35, K50.00–K50.919), anticipate that claims may be denied and provide alternative supporting documentation or an appeal rationale.

    • Examples of ICD‑10 codes listed as not covered: L20.0–L20.9 (atopic dermatitis); G35 (multiple sclerosis); K50.00–K50.919 (Crohn’s disease)
    Billing Rule

    Provide clinical trial enrollment documentation for BOS after lung transplant

    Document enrollment in an approved clinical research study for BOS after lung transplant (CMS NCD) when requesting coverage; lack of evidence of study participation may lead to denial under the CMS determination.

    • CMS NCD (4/30/2012) requires ECP for BOS after lung transplant to be provided only within qualifying clinical research studies
    Denial Risk

    Expect higher documentation burden for indications with limited evidence

    Be prepared to supply additional justification or documentation for indications with insufficient or preliminary evidence (small/nonrandomized studies); such indications may be denied or require more evidence for approval.

    • Policy notes evidence for some indications is preliminary and based on small or nonrandomized studies and may trigger noncoverage or requests for additional justification
    Note

    CPB is administrative guidance — confirm coverage with the plan

    Administrative notice: Clinical Policy Bulletins assist plan administration but do not guarantee coverage; providers remain responsible for treatment decisions and must verify member benefits and prior‑auth requirements.

    • CPB is not a contract and does not guarantee coverage; participating providers are independent and responsible for member care
    Diagnostic implicationThis FEV1 decline is considered predictive of BOS but does not in itself establish the diagnosis of BOS.
    Measurement requirementRequires two FEV1 measurements separated by a minimum of 3 weeks to document the averaged percentage decline.
    Extracorporeal photopheresis (ECP) — alternate procedural characterization (exposed leukocyte percentage)
    Exposed leukocyte proportionECP involves exposure of approximately 10–20% of the patient’s peripheral leukocytes to photo‑activated 8‑methoxypsoralen and UVA radiation before reinfusion.
    Proposed mechanismMechanism is not fully known; immune modulation may occur via exposure of T‑cell clones leading to inhibition of T‑cell–mediated autoimmunity.
    Context of descriptionThis characterization is provided in systematic reviews and case reports summarizing ECP technique and hypothesized immunologic effects.
    CLAD/BOS — definition for chronic lung allograft dysfunction and bronchiolitis obliterans syndrome (BOS)
    Definition of CLAD/BOSChronic lung allograft dysfunction (CLAD) denotes post‑transplant chronic decline in lung function; bronchiolitis obliterans syndrome (BOS) is a form of CLAD characterized by progressive decline in FEV1.
    Clinical significanceCLAD/BOS limits long‑term survival after lung transplantation and has few effective, standardized therapies.
    Response assessment exampleIn a retrospective rescue series, ECP arrested lung‑function decline in about 67% of patients with CLAD, measured by changes in FEV1 decline rate pre‑ versus post‑ECP.